Stock 688131 SHANGHAI HAOYUAN CHEMEXPRESS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Haoyuan Chemexpress Co., Ltd.

Equities

688131

CNE1000051J4

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-26 pm EDT 		5-day change 1st Jan Change
29.5 CNY -0.34% Intraday chart for Shanghai Haoyuan Chemexpress Co., Ltd. -7.15% -43.33%
Apr. 29 Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 25 Haoyuan Chemexpress to Issue 822 Million Yuan Worth of Convertible Bonds MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI HAOYUAN CHEMEXPRESS CO., LTD. Stock Shanghai Haoyuan Chemexpress Co., Ltd.
-43.33% 615M -
CSL LIMITED Stock CSL Limited
-2.10% 90.02B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-0.66% 39.15B
A-
BIOGEN INC. Stock Biogen Inc.
-15.83% 31.71B
B-
UCB Stock UCB
+62.42% 26.47B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-21.68% 14.34B
C
INCYTE CORPORATION Stock Incyte Corporation
-8.73% 12.89B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-10.32% 11.18B
D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-45.77% 10.97B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.45% 8.94B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688131 Stock
  4. Ratings Shanghai Haoyuan Chemexpress Co., Ltd.